Сердолект Uses, Dosage, Side Effects and more

Сердолект, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia. It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. It has once again been approved and should soon be available on the French and Australian market.

Сердолект is an atypical antipsychotic at least as effective as haloperidol and risperidone in the treatment of neuroleptic-responsive schizophrenia. Сердолект improves negative symptoms, and is also effective for the treatment of neuroleptic-resistant schizophrenia. Сердолект is generally well tolerated and is associated with a low rate of extrapyramidal symptoms (EPS).

Attribute	Details
Trade Name	Сердолект
Generic	Sertindole
Sertindole Other Names	Sertindol, Sertindole, Sertindolum
Type
Formula	C₂₄H₂₆ClFN₄O
Weight	Average: 440.941 Monoisotopic: 440.177917386
Groups	Approved, Investigational, Withdrawn
Therapeutic Class
Manufacturer
Available Country	Russia
Last Updated:	January 7, 2025 at 1:49 am

Uses

Сердолект is an atypical antipsychotic indicated in the treatment of schizophrenia.

Used in the treatment of schizophrenia.

Сердолект is also used to associated treatment for these conditions: Schizophrenia

How Сердолект works

Сердолект is an antipsychotic drug with affinity for dopamine D2, serotonin 5-HT2A and 5-HT2C, and alpha1-adrenoreceptors. Preclinical studies suggest that sertindole acts preferentially on limbic and cortical dopaminergic neurons and clinical trials have confirmed that sertindole is effective at a low dopamine D2 occupancy level.